Zacks Investment Research downgraded shares of NantKwest, Inc. (NASDAQ:NK) from a buy rating to a hold rating in a research note released on Wednesday, October 18th.
According to Zacks, “NantKwest, Inc. is a clinical-stage immunotherapy company. The Company’s product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc. is headquartered in Cardiff-by-the-Sea, California. “
Several other equities analysts have also recently commented on NK. Citigroup Inc. set a $3.00 price target on shares of NantKwest and gave the company a sell rating in a report on Monday, August 14th. BidaskClub cut shares of NantKwest from a hold rating to a sell rating in a report on Tuesday, August 8th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company. The stock has a consensus rating of Hold and an average price target of $5.44.
NantKwest (NK) traded down $0.02 during midday trading on Wednesday, hitting $4.23. The company’s stock had a trading volume of 88,159 shares, compared to its average volume of 148,440. The company has a current ratio of 4.92, a quick ratio of 4.92 and a debt-to-equity ratio of 0.01. NantKwest has a 52 week low of $2.71 and a 52 week high of $8.45.
WARNING: This article was originally published by BBNS and is owned by of BBNS. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://baseballnewssource.com/markets/nantkwest-inc-nk-rating-lowered-to-hold-at-zacks-investment-research/1723383.html.
In other NantKwest news, Director Steve Gorlin sold 39,604 shares of the business’s stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $5.93, for a total transaction of $234,851.72. Following the completion of the transaction, the director now owns 246,280 shares of the company’s stock, valued at approximately $1,460,440.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 70.19% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp raised its position in NantKwest by 48.3% in the second quarter. Bank of New York Mellon Corp now owns 122,211 shares of the biotechnology company’s stock worth $928,000 after purchasing an additional 39,823 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in NantKwest by 102.1% during the second quarter. Schwab Charles Investment Management Inc. now owns 105,159 shares of the biotechnology company’s stock worth $799,000 after buying an additional 53,134 shares during the last quarter. Vanguard Group Inc. grew its stake in NantKwest by 8.4% during the first quarter. Vanguard Group Inc. now owns 2,082,706 shares of the biotechnology company’s stock worth $7,394,000 after buying an additional 160,510 shares during the last quarter. Dynamic Technology Lab Private Ltd grew its stake in NantKwest by 53.4% during the first quarter. Dynamic Technology Lab Private Ltd now owns 32,939 shares of the biotechnology company’s stock worth $117,000 after buying an additional 11,465 shares during the last quarter. Finally, Balyasny Asset Management LLC bought a new stake in NantKwest during the second quarter worth about $380,000. 18.77% of the stock is owned by institutional investors and hedge funds.
NantKwest Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NantKwest Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest Inc. and related companies with our FREE daily email newsletter.